Veru Inc.
VERUHealthcare|Biotechnology|US
$2.12
+0.06 (+2.91%)
DCF Value
$0.66
Tangible Book / Share
$0.93
Cash / Share
$1.04
Financials
Financial Snapshot
Market Cap
$36.1M
Enterprise Value
$14.9M
Revenue (TTM)
$0.00
Net Income (TTM)
-$13.6M
Cash & Investments
$23.9M
Net Cash
$21.2M
Free Cash Flow (TTM)
-$26.0M
Operating CF (TTM)
-$26.0M
Debt/Equity
0.09
Cash Runway & Burn Rate
Cash on Hand
$23.9M
Quarterly Burn
$6.5M
Monthly Burn
$2.2M
Est. Runway
~3.7 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $2.4M | $3.3M | $3.8M | $6.3M | $13.6M | $122.4M | $80.2M | $9.6M | $24.9M | $18.3M | $23.9M | |
| Operating Cash Flow | -$1.7M | $982.9K | -$11.5M | -$5.5M | -$1.9M | -$15.6M | -$47.5M | -$88.0M | -$21.7M | -$30.0M | -$26.0M | |
| Free Cash Flow | -$1.7M | $849.4K | -$11.6M | -$5.6M | -$2.0M | -$15.9M | -$48.2M | -$88.7M | -$21.8M | -$30.0M | -$26.0M | |
| Capital Expenditure | -$6.4K | -$133.5K | -$50.7K | -$108.5K | -$105.8K | -$376.6K | -$733.1K | -$665.7K | -$158.3K | -$1.1K | $1.00 | |
| Financing Cash Flow | $0.00 | $0.00 | $12.1M | $8.1M | $9.3M | $109.7M | $1.1M | $11.1M | $36.8M | -$4.2M | $23.3M |
R&D Spending
R&D (TTM)
$11.8M
R&D Intensity
—
R&D Growth vs Prior
-24.5%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $22.1M | $13.7M | $15.9M | $31.8M | $42.6M | $61.3M | $39.4M | $16.3M | $16.9M | $0.00 | $0.00 | |
| R&D Expense | $99.4K | $3.5M | $10.9M | $13.7M | $16.9M | $32.7M | $70.6M | $51.2M | $12.8M | $15.6M | $11.8M | |
| R&D % of Revenue | 0.4% | 25.7% | 68.4% | 43.2% | 39.8% | 53.4% | 179.5% | 314.2% | 75.8% | — | — | |
| SG&A | $8.7M | $11.1M | $14.8M | $14.3M | $14.5M | $20.7M | $43.2M | $48.1M | $31.2M | $19.9M | $16.1M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $22.1M | $13.7M | $15.9M | $31.8M | $42.6M | $61.3M | $39.4M | $16.3M | $16.9M | $0.00 | $0.00 | |
| Cost of Revenue | $8.8M | $6.6M | $7.1M | $10.1M | $11.8M | $13.3M | $8.8M | $8.7M | $11.0M | $0.00 | $56.4K | |
| Gross Profit | $13.3M | $7.0M | $8.8M | $21.7M | $30.8M | $47.9M | $30.6M | $7.6M | $5.9M | $0.00 | -$56.4K | |
| R&D | $99.4K | $3.5M | $10.9M | $13.7M | $16.9M | $32.7M | $70.6M | $51.2M | $12.8M | $15.6M | $11.8M | |
| SG&A | $8.7M | $11.1M | $14.8M | $14.3M | $14.5M | $20.7M | $43.2M | $48.1M | $31.2M | $19.9M | $16.1M | |
| Operating Income | $3.0M | -$8.5M | -$20.9M | -$6.4M | -$14.7M | $13.0M | -$83.2M | -$93.8M | -$36.9M | -$24.8M | -$19.2M | |
| Interest Expense | $3.3M | $2.0M | $3.0M | $4.7M | $4.6M | $4.9M | $4.4M | $2.4M | $607.5K | $0.00 | $0.00 | |
| Pretax Income | $2.8M | -$8.6M | -$23.1M | -$12.3M | -$20.1M | $4.3M | -$83.8M | -$92.7M | -$37.1M | -$15.7M | -$14.1M | |
| Net Income | $344.7K | -$6.6M | -$23.9M | -$12.0M | -$19.0M | $7.4M | -$83.8M | -$93.2M | -$37.8M | -$22.7M | -$13.6M | |
| EPS (Diluted) | 0.10 | -2.48 | -4.44 | -1.90 | -2.84 | 0.90 | -10.49 | -10.96 | -2.80 | -1.55 | -0.60 | |
| EBITDA | $4.9M | -$8.1M | -$19.7M | -$7.1M | -$15.0M | $9.3M | -$79.2M | -$90.0M | -$36.2M | -$35.4M | -$27.0M | |
| Shares Out. (M) | 2.89 | 3.46 | 5.39 | 6.33 | 6.68 | 8.38 | 8.01 | 8.50 | 13.49 | 14.65 | 23.05 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.4M | $3.3M | $3.8M | $6.3M | $13.6M | $122.4M | $80.2M | $9.6M | $24.9M | $15.8M | $23.9M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $2.5M | $0.00 | |
| Total Current Assets | $18.3M | $10.3M | $11.2M | $16.8M | $27.0M | $151.8M | $104.0M | $22.9M | $35.2M | $18.9M | $27.2M | |
| Total Assets | $38.6M | $55.3M | $48.5M | $53.6M | $51.5M | $178.1M | $135.4M | $50.0M | $60.4M | $29.8M | $37.0M | |
| Total Current Liabilities | $3.3M | $5.5M | $13.6M | $14.0M | $14.7M | $15.8M | $38.7M | $17.8M | $11.9M | $7.8M | $6.2M | |
| Long-Term Debt | $0.00 | $0.00 | $4.5M | $6.7M | $5.6M | $9.4M | $9.7M | $8.9M | $8.9M | $0.00 | $1.9M | |
| Total Liabilities | $4.7M | $6.9M | $19.0M | $21.3M | $21.4M | $25.9M | $52.6M | $30.3M | $28.1M | $11.5M | $8.7M | |
| Stockholders' Equity | $33.9M | $48.5M | $29.5M | $32.3M | $30.1M | $152.3M | $82.8M | $19.7M | $32.3M | $18.3M | $28.4M | |
| Retained Earnings | -$27.7M | -$34.3M | -$58.2M | -$70.2M | -$89.2M | -$81.8M | -$163.6M | -$256.8M | -$294.6M | -$317.3M | -$332.4M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.7M | $982.9K | -$11.5M | -$5.5M | -$1.9M | -$15.6M | -$47.5M | -$88.0M | -$21.7M | -$30.0M | -$26.0M | |
| Capital Expenditure | -$6.4K | -$133.5K | -$50.7K | -$108.5K | -$105.8K | -$376.6K | -$733.1K | -$665.7K | -$158.3K | -$1.1K | $1.00 | |
| Free Cash Flow | -$1.7M | $849.4K | -$11.6M | -$5.6M | -$2.0M | -$15.9M | -$48.2M | -$88.7M | -$21.8M | -$30.0M | -$26.0M | |
| Investing Cash Flow | -$6.4K | -$90.4K | -$50.7K | -$108.5K | -$105.8K | $14.6M | $4.3M | $6.3M | $146.2K | $25.1M | $11.6M | |
| Financing Cash Flow | $0.00 | $0.00 | $12.1M | $8.1M | $9.3M | $109.7M | $1.1M | $11.1M | $36.8M | -$4.2M | $23.3M | |
| Issuance of Stock | $0.00 | $0.00 | $3.0M | $9.4M | $13.8M | $108.1M | $1.1M | $6.0M | $35.3M | $0.00 | $0.00 | |
| Repurchase of Stock | $0.00 | $0.00 | -$77.8K | $0.00 | -$50.3K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $9.4M | -$4.9M | -$4.4M | -$19.4K | -$9.1K | $133.0K | -$133.0K | -$4.2M | $4.2M | |
| Stock Based Comp. | $499.9K | $756.3K | $1.6M | $1.9M | $2.6M | $5.1M | $11.2M | $17.9M | $13.6M | $8.1M | $1.5M | |
| Net Change in Cash | -$1.7M | $892.5K | $481.9K | $2.5M | $7.3M | $108.8M | -$42.2M | -$70.6M | $15.3M | -$9.1M | $8.9M |
Dilution Tracker
Shares outstanding grew 119.4% over 5 years — significant dilution
Shares Outstanding
17M
5-Year Share Growth
+119.4%
Stock Issuance (TTM)
$0.00
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 2.89 | 3.46 | 5.39 | 6.33 | 6.68 | 8.38 | 8.01 | 8.50 | 13.49 | 14.65 | 23.05 | |
| Change vs Prior % | — | 19.8% | 55.5% | 17.6% | 5.4% | 25.5% | -4.4% | 6.1% | 58.7% | 8.6% | 57.4% | |
| Stock Issuance | $0.00 | $0.00 | $3.0M | $9.4M | $13.8M | $108.1M | $1.1M | $6.0M | $35.3M | $0.00 | $0.00 | |
| Stock Repurchase | $0.00 | $0.00 | -$77.8K | $0.00 | -$50.3K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $499.9K | $756.3K | $1.6M | $1.9M | $2.6M | $5.1M | $11.2M | $17.9M | $13.6M | $8.1M | $1.5M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 60.3% | 51.4% | 55.4% | 68.1% | 72.3% | 78.2% | 77.7% | 46.4% | 34.7% | — | — | |
| Operating Margin % | 13.6% | -62.2% | -131.6% | -20.2% | -34.6% | 21.2% | -211.5% | -575.5% | -218.6% | — | — | |
| Net Margin % | 1.6% | -48.4% | -150.9% | -37.8% | -44.5% | 12.1% | -212.9% | -571.6% | -223.9% | — | — | |
| EBITDA Margin % | 22.3% | -59.5% | -124.0% | -22.5% | -35.1% | 15.2% | -201.3% | -552.1% | -214.4% | — | — | |
| FCF Margin % | -7.8% | 6.2% | -73.1% | -17.6% | -4.8% | -26.0% | -122.6% | -544.1% | -129.3% | — | — | |
| ROE % | 1.0% | -13.6% | -81.2% | -37.2% | -63.0% | 4.9% | -101.2% | -473.4% | -117.0% | -124.0% | -45.9% | |
| ROA % | 0.9% | -12.0% | -49.4% | -22.4% | -36.8% | 4.2% | -61.9% | -186.2% | -62.6% | -76.2% | -36.8% | |
| ROIC % | 1.0% | -13.1% | -50.2% | -14.0% | -31.5% | 7.8% | -84.3% | -274.9% | -72.9% | -108.5% | -60.6% | |
| R&D / Revenue % | 0.4% | 25.7% | 68.4% | 43.2% | 39.8% | 53.4% | 179.5% | 314.2% | 75.8% | — | — |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -32.1% | -38.3% | 16.2% | 100.5% | 33.9% | 43.8% | -35.8% | -58.6% | 3.6% | -100.0% | |
| Gross Profit | -29.6% | -47.4% | 25.1% | 146.6% | 42.2% | 55.7% | -36.2% | -75.3% | -22.6% | -100.0% | |
| Operating Income | -54.4% | -381.4% | -145.7% | 69.2% | -129.1% | 188.0% | -741.5% | -12.7% | 60.6% | 33.0% | |
| Net Income | -92.1% | -2018.1% | -262.0% | 49.8% | -57.9% | 139.0% | -1233.0% | -11.2% | 59.4% | 39.9% | |
| EPS (Diluted) | -93.3% | -2583.5% | -79.0% | 57.2% | -49.5% | 131.7% | -1265.6% | -4.5% | 74.5% | 44.6% | |
| Operating Cash Flow | -10.7% | 157.3% | -1274.7% | 52.5% | 64.8% | -706.7% | -205.1% | -85.3% | 75.4% | -38.6% | |
| Free Cash Flow | -2.2% | 149.4% | -1465.3% | 51.8% | 63.6% | -683.3% | -202.5% | -83.8% | 75.4% | -37.6% | |
| R&D Expense | -54.8% | 3425.9% | 209.6% | 26.7% | 23.2% | 93.1% | 116.1% | -27.5% | -75.0% | 21.7% | |
| SG&A Expense | -27.9% | 26.6% | 33.8% | -3.2% | 1.0% | 42.6% | 108.8% | 11.3% | -35.1% | -36.0% | |
| Total Assets | 3.1% | 43.2% | -12.4% | 10.7% | -3.9% | 245.6% | -24.0% | -63.0% | 20.8% | -50.6% | |
| Book Value / Share | 1.9% | 18.2% | -60.9% | -6.7% | -11.7% | 342.6% | -48.2% | -77.6% | 3.5% | -47.8% | |
| Debt | 0.0% | 0.0% | 0.0% | 8.7% | 16.7% | -2.8% | 15.5% | -9.3% | -3.8% | -77.5% | |
| Diluted Shares | 0.0% | 19.8% | 55.5% | 17.6% | 5.4% | 25.5% | -4.4% | 6.1% | 58.7% | 8.6% |
Valuation
P/E (TTM)At Loss
P/S0.00
10Y Low / Med / High1.58 / 4.45 / 23.45
P/B1.72
10Y Low / Med / High1.03 / 3.21 / 11.15
EV/EBITDAAt Loss
EV/Revenue0.00
10Y Low / Med / High1.47 / 4.91 / 21.82
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$0.66
Tangible Book / Share
$0.93
Net Current Assets / Share
$1.09
Graham Net-Net
$0.66
Cash / Share
$1.04
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | 122.00 | -10.67 | -2.95 | -11.37 | -9.23 | 85.30 | -10.98 | -0.66 | -2.75 | -2.45 | -3.53 | |
| P/S Ratio | 1.58 | 6.72 | 4.45 | 4.30 | 4.11 | 10.62 | 23.45 | 3.75 | 6.14 | 0.00 | 0.00 | |
| P/B Ratio | 1.03 | 1.89 | 2.39 | 4.23 | 5.81 | 4.27 | 11.15 | 3.10 | 3.21 | 3.04 | 1.72 | |
| EV/EBITDA | 6.62 | -10.90 | -3.96 | -19.96 | -11.72 | 58.10 | -10.84 | -0.73 | -2.56 | -1.21 | -0.55 | |
| EV/Revenue | 1.47 | 6.48 | 4.91 | 4.48 | 4.12 | 8.85 | 21.82 | 4.04 | 5.49 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-11.79
Distress
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2027 | FY2028 | FY2029 |
|---|---|---|---|
| Revenue | $4.0M | $12.5M | $125.0M |
| Net Income | -$12.2M | -$6.8M | -$8.8M |
| EPS | $-0.83 | $-0.46 | $-0.60 |
| # Analysts (EPS) | 2 | 2 | 1 |
Dividends
Frequency
Quarterly
Recent Payments
| Ex-Date | Pay Date | Amount | Frequency |
|---|---|---|---|
| Apr 28, 2014 | May 7, 2014 | $0.07 | Quarterly |
| Jan 27, 2014 | Feb 5, 2014 | $0.07 | Quarterly |
| Oct 28, 2013 | Nov 6, 2013 | $0.07 | Quarterly |
| Jul 29, 2013 | Aug 7, 2013 | $0.07 | Quarterly |
| Apr 29, 2013 | May 8, 2013 | $0.07 | Quarterly |
| Jan 28, 2013 | Feb 6, 2013 | $0.06 | Quarterly |
| Oct 29, 2012 | Nov 7, 2012 | $0.06 | Quarterly |
| Jul 30, 2012 | Aug 8, 2012 | $0.06 | Quarterly |
| Apr 30, 2012 | May 9, 2012 | $0.06 | Quarterly |
| Jan 30, 2012 | Feb 9, 2012 | $0.05 | Quarterly |
| Oct 31, 2011 | Nov 9, 2011 | $0.05 | Quarterly |
| Jul 29, 2011 | Aug 9, 2011 | $0.05 | Quarterly |
| Apr 29, 2011 | May 10, 2011 | $0.05 | Quarterly |
| Jan 27, 2011 | Feb 7, 2011 | $0.05 | Quarterly |
| Nov 1, 2010 | Nov 10, 2010 | $0.05 | Quarterly |
| Aug 2, 2010 | Aug 11, 2010 | $0.05 | Quarterly |
| Apr 21, 2010 | May 12, 2010 | $0.05 | Quarterly |
| Jan 27, 2010 | Feb 16, 2010 | $0.05 | Quarterly |
Revenue Segments
By Product
| Segment | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Preboost Segment | $884.0K | $2.0M | $862.8K | — | — | — |
| Other Products | — | — | — | $2.4K | $13.0K | — |
| Global public health sector | — | — | — | — | — | $14.5M |
| U.S. prescription channel | — | — | — | — | — | $2.4M |
By Geography
| Segment | 2018 | 2019 | 2020 | 2021 | 2022 | 2024 |
|---|---|---|---|---|---|---|
| K | $1.0M | — | — | — | — | — |
| Other Countries | $4.5M | $14.5M | $12.3M | $12.3M | $7.9M | — |
| U | $5.2M | $17.3M | $30.3M | $48.9M | $31.4M | — |
| Z | $2.2M | — | — | — | — | — |
| BRAZIL | — | — | — | — | — | $2.8M |
| MOZAMBIQUE | — | — | — | — | — | $2.2M |
| Other Geographical Areas | — | — | — | — | — | $4.7M |
| SOUTH AFRICA | — | — | — | — | — | $1.9M |
| UNITED STATES | — | — | — | — | — | $5.4M |